News | October 19, 2011

Data Demonstrates LipiScan Imaging System Detects Lipid Core Plaques

October 19, 2011 - A new study published in Circulation: Cardiovascular Interventions shows lesions with large lipid cores are associated with a 50 percent risk of heart attack in patients undergoing coronary stent implantation.

Near-infrared spectroscopy (NIRS) with the InfraReDX LipiScan system was shown to rapidly and accurately detect extensive lipid core plaques (LCPs) that are linked to an increased risk of heart attack during or following percutaneous coronary intervention (PCI). The system is the first and only system approved by the U.S. Food and Drug Administration (FDA) to provide interventional cardiologists with a chemogram, a two-dimensional map of LCP, within the imaged vessel using NIRS.

"Although PCI routinely achieves excellent angiographic results, too many cases continue to suffer from peri-procedural no-reflow and myocardial infarction," said James A. Goldstein, M.D., FACC, director of research and education, division of cardiology, Beaumont Hospital, Royal Oak, Mich., and lead author of the study. "This study utilizing InfraReDx's first-generation LipiScan system with NIR spectroscopy permitted immediate identification of large lipid core plaques known to complicate stenting and suspected to cause most heart attacks. By identifying and quantifying these dangerous plaques that are prone to embolization, the LipiScan system holds the potential to improve patient outcomes and prevent complications in cardiac procedures."

PCI is associated with a peri-procedural heart attack in three to 15 percent of cases. In many cases, these heart attacks result from distal embolization of LCP contents. These heart attacks are detected by procedural elevations of cardiac biomarkers specific for death of heart muscle tissue. LCP is a fatty coronary artery plaque suspected to be vulnerable to rupture, to cause most heart attacks and to complicate stenting procedures either during or post-intervention. Peri-procedural heart attacks are associated with adverse long-term outcomes and in some cases cause immediate adverse events.

The published study shows that in patients with coronary artery disease, PCI of lesions with a large lipid core is associated with a 50 percent risk of heart attack during or post-procedure compared to only a 4.2 percent risk for lesions without a large lipid core. A
large LCP was defined as a maximum lipid core burden index (LCBI) within a 4mm segment of ?500, which corresponds to a LCP which on average is 4 mm long and occupies 180 degrees of the vessel circumference. Sixty-two patients meeting study criteria were selected from the COLOR Registry (NCT00831116). There were no major adverse events attributed to the use of the LipiScan system.

The use of NIR spectroscopy with the LipiScan Coronary Imaging System permitted the immediate identification and quantification of LCPs whose presence could not be determined by coronary angiography. Baseline variables also correlated poorly with the presence of a large LCP, with elevation of plasma LDL levels as the only statistically significant association. Patients with a large LCP had a 12-fold increase in relative risk (95 percent CI 3.3 to 48, p=0.0002) of peri-procedural heart attacks. In contrast, plaque complexity identified on coronary angiography, a finding often considered to be an index of increased risk of a PCI-induced complication, was associated with a relative risk of only 3.5 (CI 0.91 to 14), a difference that was not statistically significant.

Results of the published study are consistent with prior findings with other intracoronary imaging methods, but the LipiScan System identified a much higher relative risk and requires no offline analysis or expert interpretation. These findings support the concept that LCPs may be prone to complications after stenting, and their detection in the catheterization lab prior to angioplasty may help guide the interventional treatment strategy. As stated in the study article, "the ability to identify stenoses with varying levels of risk of complications when stented would indicate that LCP presence or absence might play a role in determining whether or not a lesion should be treated."

The paper titled "Detection of Lipid-core Plaques by Intra-Coronary Near-Infrared Spectroscopy Identifies High Risk of Peri-Procedural
Myocardial Infarction" was published online at http://circinterventions.ahajournals.org/content/early/2011/10/04/CIRCINTERVENTIONS.111.963264.abstract and appears in today's print edition of the journal.

Editor’s note: James A. Goldstein, M.D., is a consultant for and owns equity in InfraReDx Inc.

For more information: www.infraredx.com

Related Content

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

News | Cardiovascular Clinical Studies | July 22, 2020
July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to re
The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp